179 related articles for article (PubMed ID: 17204711)
1. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software.
Kolbert KS; Pentlow KS; Pearson JR; Sheikh A; Finn RD; Humm JL; Larson SM
J Nucl Med; 2007 Jan; 48(1):143-9. PubMed ID: 17204711
[TBL] [Abstract][Full Text] [Related]
2. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.
Sgouros G; Kolbert KS; Sheikh A; Pentlow KS; Mun EF; Barth A; Robbins RJ; Larson SM
J Nucl Med; 2004 Aug; 45(8):1366-72. PubMed ID: 15299063
[TBL] [Abstract][Full Text] [Related]
3. Acquisition settings for PET of 124I administered simultaneously with therapeutic amounts of 131I.
Lubberink M; van Schie A; de Jong HW; van Dongen GA; Teule GJ
J Nucl Med; 2006 Aug; 47(8):1375-81. PubMed ID: 16883019
[TBL] [Abstract][Full Text] [Related]
4. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
Med Phys; 2016 Oct; 43(10):5279-5287. PubMed ID: 28105713
[TBL] [Abstract][Full Text] [Related]
5. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.
Jentzen W; Freudenberg L; Eising EG; Sonnenschein W; Knust J; Bockisch A
J Nucl Med; 2008 Jun; 49(6):1017-23. PubMed ID: 18483099
[TBL] [Abstract][Full Text] [Related]
6. 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer.
Freudenberg LS; Jentzen W; Marlowe RJ; Koska WW; Luster M; Bockisch A
Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):690-3. PubMed ID: 18058605
[TBL] [Abstract][Full Text] [Related]
7. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
[TBL] [Abstract][Full Text] [Related]
8. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
Med Phys; 2016 Oct; 43(10):5279. PubMed ID: 27782699
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer.
Sgouros G; Hobbs RF; Atkins FB; Van Nostrand D; Ladenson PW; Wahl RL
Eur J Nucl Med Mol Imaging; 2011 May; 38 Suppl 1(Suppl 1):S41-7. PubMed ID: 21484384
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I.
Pettinato C; Monari F; Nanni C; Allegri V; Marcatili S; Civollani S; Cima S; Spezi E; Mazzarotto R; Fanti S
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):509-14. PubMed ID: 23358403
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
Eschmann SM; Reischl G; Bilger K; Kupferschläger J; Thelen MH; Dohmen BM; Besenfelder H; Bares R
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):760-7. PubMed ID: 12029549
[TBL] [Abstract][Full Text] [Related]
12. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
[TBL] [Abstract][Full Text] [Related]
13. Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
Wierts R; Brans B; Havekes B; Kemerink GJ; Halders SG; Schaper NN; Backes WH; Mottaghy FM; Jentzen W
J Nucl Med; 2016 Jul; 57(7):1027-32. PubMed ID: 26917706
[TBL] [Abstract][Full Text] [Related]
14. Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET.
Hobbs RF; Jentzen W; Bockisch A; Sgouros G
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):79-91. PubMed ID: 23474639
[TBL] [Abstract][Full Text] [Related]
15. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry.
Prideaux AR; Song H; Hobbs RF; He B; Frey EC; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2007 Jun; 48(6):1008-16. PubMed ID: 17504874
[TBL] [Abstract][Full Text] [Related]
16. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact.
Freudenberg LS; Jentzen W; Görges R; Petrich T; Marlowe RJ; Knust J; Bockisch A
Nuklearmedizin; 2007; 46(4):121-8. PubMed ID: 17690789
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer.
Capoccetti F; Criscuoli B; Rossi G; Ferretti F; Manni C; Brianzoni E
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):536-45. PubMed ID: 19910907
[TBL] [Abstract][Full Text] [Related]
18. Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.
Jentzen W; Hobbs RF; Stahl A; Knust J; Sgouros G; Bockisch A
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):884-95. PubMed ID: 20069293
[TBL] [Abstract][Full Text] [Related]
19. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.
Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S
Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357
[TBL] [Abstract][Full Text] [Related]
20. Implementation and evaluation of patient-specific three-dimensional internal dosimetry.
Kolbert KS; Sgouros G; Scott AM; Bronstein JE; Malane RA; Zhang J; Kalaigian H; McNamara S; Schwartz L; Larson SM
J Nucl Med; 1997 Feb; 38(2):301-8. PubMed ID: 9025759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]